|
Author (year) |
Subjects | Type of PD | Amendment | Outcomes |
|---|---|---|---|---|
| Quirynen et al. (1995) [2] |
10 | SCP | Initial Protocol (FMS + CHX 2wks) |
For deep pockets : more reduction of PPD in T group / C group (p < 0.05). |
| Bollen et al. (1998) [5] |
16 | SCP | FMS with CHX 2mths | better results than in initial FMD protocol. |
| Quirynen et al. (2000) [6] |
36 | SCP | FMD without CHX |
FMS alone > QRSP: more reduction of PPD and CAL gain (p<0.001; p <0.001). |
| Apatzidou et al. (2004) [7] |
40 | SCP | FMD without CHX | Both therapies (FMS alone and QRSP) improved clinical indices. |
| Quirynen et al. (2006) [10] |
71 | MCP | FMD with AF | Less reduction of PPD with AF alone ( FMS + AF < FMS + CHX or / FMS + CHX +AF p<0.05) . |
| Wang et al. (2006) [11] |
36 | CP | FMD with PId |
Less reduction of Pg and Aa with Id versus Water or QRSP (p<0.005;P<0.005). |
| Gomi et al. (2007) [14] |
34 | SCP | FMD + AZT alone |
Significant improvement of clinical parameters with AZT (PPD, BOP, GCF) (P<0.001). |
| Cavalca al. (2009) [12] |
50 | MCP | FMD with EO | Efficacy of EO to reduce PPD, PI and BOP. |
|
Cortelli et al. (2009) [13] |
50 | MCP | FMD with EO | At 2 and 6 months, no significance difference between EO and placebo regarding microbiology parameters. |
| Yashima et al. (2009) [15] |
30 | CP | FMD + AZT alone | Significant improvement of clinical parameters with AZT (P<0.01; P<0.05). |
| Cionca et al. (2009) [16] |
47 | CP | FMD + Amox & MTZ |
At 6 months, less sites with PDP > 4 mm with Amox +MTZ versus placebo. |
| Swierkot et al. (2009) [8] |
25 | CP | FMD without CHX | At 1 and 2 months, more reduction of PPD, BOP in FMD with or without CHX versus QRSP alone. |
| Cionca et al. (2010) [17] |
51 | CP | FMD + Amox & MTZ | Significant reduction of Pg (P = 0,013) and Tf (P = 0,007) with FMD combined to Amox&MTZ compared to placebo or FMD alone. |
| Sigusch et al. (2010) [23] |
24 | CP | FMD with PTD | Better improvements of PPD and CAL gain with FMD combined to PTD versus FMD alone. |
| Varela et al. (2011) [18] |
25 | AP | FMD + Amox & MTZ | Better clinical improvements (PPD, CAL) on sites with PDi <5mm (p <0.03) using FMD combined to Amox&MTZ versus FMD alone. |
| Aimetti et al. (2012) [19] |
39 | AP | FMD + Amox & MTZ | Up to 6 months, better reduction of Aa + red complexes in site with PDi > 5 mm using FMD combined to Amox&MTZ versus FMD alone . |
| Preus et al. (2013) [20] |
184 | MCP & SCP | FMD + MTZ alone | Up to 12 months in groups with MTZ, sites with PDi > 5 mm obtained better PPD reduction + better CAL gain. |
| Santos et al. (2013) [9] |
38 | CP | FMD without CHX | Up to 12 months similar clinical improvement with or without CHX. |
| Teughels et al. (2013) [21] |
30 | CP | FMD + PRB12 wks | Reduction in surgical treatment need with PRB. |
| Keestra et al. (2014) [24] |
24 | CP | FMD + periodontal dressing | Reduction of postoperative pain with adjunction of periodontal dressing . |
| Fonseca et al. (2015) [22] |
85 | CP | FMD + AZT | Addition of AZT did not provide additional clinical benefit compared to the FMD technique alone. |